Moderna, Inc. (MRNA) Announced Q1 2026 Earnings on May 1, 2026, Reporting "total revenue was $400 million".

Moderna, Inc. reported financial results for the first quarter of 2026.

Management noted that "total revenue was $400 million" in the quarter. "Net loss for the quarter was $1.3 billion" on a GAAP basis.

The company "ended the first quarter with cash and investments of $7.5 billion". "Cost of sales for the quarter was $955 million," which management stated "includes $878 million related to our previously disclosed litigation settlement". "R&D expenses for the quarter were $649 million," and "SG&A expenses for the quarter were $173 million".During the quarter, Moderna noted the approval of mCOMBRIAX in the European Union, describing it as "the first flu plus COVID combo vaccine approved in the world". Management highlighted that "we now have 4 approved products". The company also "secured key regulatory approvals in the European Union, including mNEXSPIKE". Additionally, the company "delivered our first shipment under a strategic partnership in the United Kingdom". In oncology, management stated they "initiated a new Phase III clinical trial in non-small cell lung cancer for patients with Stage 1 disease".Looking ahead, management stated they expect "total revenue to grow up to 10% in 2026". For the second quarter, they "are expecting revenue of between $50 million and $100 million". The full year "cost of sales projection has increased from $0.9 billion to $1.8 billion". For the full year, "R&D expenses are still anticipated to be approximately $3 billion," and "SG&A expenses are still expected to be approximately $1 billion". The company stated "we expect to end 2026 with between $4.5 billion to $5 billion of cash and investments".